Bispecific T-Cell Engaging Antibodies for Cancer Therapy
Abstract
There is increasing evidence that T cells are able to control tumor growth and survival in cancer patients, both in early and late stages of the disease. However, tumor-specific T-cell responses are difficult to mount and sustain in cancer patients, and are limited by numerous immune escape mechanisms of tumor cells selected during immunoediting. An alternative approach to engage T cells for cancer therapy are antibodies, which are bispecific for a surface target antigen on cancer cells, and for CD3 on T cells. These are capable of connecting any kind of cytotoxic T cell to a cancer cell, independently of T-cell receptor specificity, costimulation, or peptide antigen presentation. Here, we review the principle of a new class of bispecific antibodies called BiTE (for “bispecific T-cell engager”) antibodies. Recent results from clinical studies with a CD19/CD3-bispecific BiTE antibody suggest that this therapeutic paradigm is finally showing promise for treatment of both bulky and minimal residual disease. [Cancer Res 2009;69(12):4941–4]
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Most tumor cell lines can be lysed in the presence of 0.2 to 2 pM of BiTEs for half maximal target cell lysis.
“Indeed, most tumor cell lines can be lysed in the presence of 0.2 to 2 pM of BiTEs for half maximal target cell lysis.”
From Bispecific antibodies for cancer therapy: The light at the end of the tunnel? (2009) · cites this paper as [46]
BiTEs do not require any kind of pre- or co-stimulation of effector T cells.
“The most impressive property of this class of molecules, beside the absence of requirement for any kind of pre or co stimulation of effector T cells, is the low concentration required to achieve anti-tumor activity.”
From Bispecific antibodies for cancer therapy: The light at the end of the tunnel? (2009) · cites this paper as [46]
Cites
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516 · see citing works
Immunosuppressive Strategies that are Mediated by Tumor Cells
Rabinovich, G. A., Gabrilovich, D. I., & Sotomayor, E. M. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141609 · Cited by 1,699 · see citing works
Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody
Bargou, R., Leo, E., Zugmaier, G., Klinger, M., Goebeler, M., Knop, S., Noppeney, R., Viardot, A., Hess, G., Schuler, M., et al. (2008) · Science · doi:10.1126/science.1158545 · Cited by 1,078 · see citing works
Self-citationImproving the efficacy of antibody-based cancer therapies
Carter, P. M. (2001) · Nature reviews. Cancer · doi:10.1038/35101072 · Cited by 833 · see citing works
Nuclear signalling by tumour-associated antigen EpCAM
Maetzel, D., Denzel, S., Mack, B., Canis, M., Went, P., Benk, M., Kieu, C., Papior, P., Baeuerle, P. A., Münz, M., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1824 · Cited by 719 · see citing works
Self-citationHybrid antibodies can target sites for attack by T cells
Staerz, U. D., Kanagawa, O., & Bevan, M. J. (1985) · Nature · doi:10.1038/314628a0 · Cited by 492 · see citing works
In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor
Boissonnas, A., Fetler, L., Zeelenberg, I. S., Hugues, S., & Amigorena, S. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20061890 · Cited by 378 · see citing works
Mack, M., Riethmüller, G., & Kufer, P. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.15.7021 · Cited by 351 · see citing works
Dreier, T., Lorenczewski, G., Brandl, C., Hoffmann, P., Syring, U., Hanakam, F., Kufer, P., Riethmüller, G., Bargou, R. C., & Baeuerle, P. A. (2002) · International Journal of Cancer · doi:10.1002/ijc.10557 · Cited by 348 · see citing works
Self-citationBrischwein, K., Schlereth, B., Guller, B., Steiger, C., Wolf, A., Lutterbuese, R., Offner, S., Locher, M., Urbig, T., Raum, T., et al. (2006) · Molecular Immunology · doi:10.1016/j.molimm.2005.07.034 · Cited by 256 · see citing works
Self-citationBrischwein, K., Parr, L., Pflanz, S., Volkland, J., Lumsden, J., Klinger, M., Locher, M., Hammond, S. A., Kiener, P., Kufer, P., et al. (2007) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318156750c · Cited by 187 · see citing works
Self-citationMode of cytotoxic action of T cell-engaging BiTE antibody MT110
Haas, C., Krinner, E., Brischwein, K., Hoffmann, P., Lutterbüse, R., Schlereth, B., Kufer, P., & Baeuerle, P. A. (2009) · Immunobiology · doi:10.1016/j.imbio.2008.11.014 · Cited by 179 · see citing works
Self-citationBiTE: Teaching antibodies to engage T-cells for cancer therapy.
Baeuerle, P. A., Kufer, P., & Bargou, R. C. (2009) · PubMed · Cited by 159 · see citing works
Self-citationWahlin, B. E., Sander, B., Christensson, B., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1734 · Cited by 151 · see citing works
Clinical experience with CD64-directed immunotherapy. An overview
Curnow, R. T. (1997) · Cancer Immunology, Immunotherapy · doi:10.1007/s002620050435 · Cited by 141 · see citing works
Targeted Therapies to Improve Tumor Immunotherapy
Begley, J. L., & Ribas, A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4804 · Cited by 118 · see citing works
Single chain antibody variable regions
Bird, R. E. (1991) · Trends in biotechnology · doi:10.1016/0167-7799(91)90044-i · Cited by 116 · see citing works
Recombinant bispecific antibodies for cellular cancer immunotherapy.
Müller, D., & Kontermann, R. E. (2007) · PubMed · Cited by 83 · see citing works
Update on anti-CTLA-4 antibodies in clinical trials
Langer, L., Clay, T. M., & Morse, M. A. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.8.1245 · Cited by 73 · see citing works
Meidenbauer, N., Zippelius, A., Pittet, M. J., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1341 · Cited by 59 · see citing works
BiTE: A new class of antibodies that recruit T-cells
Baeuerle, P. A., Reinhardt, C., & Kufer, P. (2008) · Drugs of the Future · doi:10.1358/dof.2008.033.02.1172578 · Cited by 37 · see citing works
Self-citationTopp, M. S., Goekbuget, N., Kufer, P., et al. (2008) · Blood · doi:10.1182/blood.v112.11.1926.1926 · Cited by 26 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Targeting neoantigens to augment antitumour immunity
Yarchoan, M., Johnson, B. A., Lutz, E. R., Laheru, D. A., & Jaffee, E. M. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.154 · Cited by 997 · see citing works
Aptamer-based targeted therapy
Zhu, G., & Chen, X. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.08.005 · Cited by 522 · see citing works
Bispecific antibodies for cancer therapy: The light at the end of the tunnel?
Chames, P., & Baty, D. (2009) · mAbs · doi:10.4161/mabs.1.6.10015 · Cited by 336 · see citing works
Developments and Challenges for mAb-Based Therapeutics
Goswami, S., Wang, W., Arakawa, T., & Ohtake, S. (2013) · Antibodies · doi:10.3390/antib2030452 · Cited by 144 · see citing works
- Authors
- Baeuerle, P. A., & Reinhardt, C.
- Affiliations
- Micromet Inc., Bethesda, Maryland
- Venue
- Cancer Research
- Published
- 2009-06-15
- Volume
- 69
- Issue
- 12
- Pages
- 4941-4944
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2111742915
- Cited by
- 592
- References
- 22
- Citations by year
- 2026: 33 · 2025: 34 · 2024: 23 · 2023: 26 · 2022: 33 · 2021: 55 · 2020: 50 · 2019: 45 · 2018: 33 · 2017: 45 · 2016: 30 · 2015: 45 · 2014: 36 · 2013: 36 · 2012: 26
- FWCI
- 17.04
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- bispecific T-cell engagers, bispecific antibodies, CD3, CD19, T-cell engagers, cancer immunotherapy, tumor immune evasion, immunoediting, minimal residual disease, bulky disease, T cell cytotoxicity
- MeSH terms
- Humans, Neoplasms, T-Lymphocytes, Antibodies, Bispecific
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
